/
OVID
$2.72+$0.17 (+6.67%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$475.9M
187M shares
52-week range
$0.30 – $3.11
86% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.44%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-1.23
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $12.6M | $208.4M | $1.5M | $392.0K | $566.0K | $7.3M |
| Cost of revenue | $141.7K | $0 | $0 | $0 | $0 | $0 | $0 | $300.0K |
| Gross profit | −$142.0K | $0 | $12.6M | $208.4M | $1.5M | $392.0K | $566.0K | $7.0M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 95.9% |
| R&D | $33.8M | $46.9M | $64.1M | $46.9M | $24.6M | $28.6M | $36.8M | $25.6M |
| Operating income | −$52.9M | −$61.4M | −$81.4M | $124.2M | −$55.5M | −$59.3M | −$61.9M | −$42.4M |
| EBITDA | −$52.8M | −$61.2M | −$81.1M | $124.4M | −$54.2M | −$57.0M | −$57.8M | −$17.1M |
| Net income | −$52.0M | −$60.5M | −$81.0M | $122.8M | −$54.2M | −$52.3M | −$26.4M | −$17.4M |
| Net margin | — | — | -642.3% | 58.9% | -3604.7% | -13351.8% | -4670.1% | -240.1% |
| EPS (diluted) | -2.11 | -1.51 | -1.39 | 1.76 | -0.77 | -0.74 | -0.37 | -0.24 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $134375 | $-0.48 | $-0.83–$-0.39 | 8 |
| 2027 | $187500 | $-0.53 | $-1.08–$-0.35 | 7 |
| 2028 | $230000 | $-0.66 | $-1.18–$-0.36 | 6 |
| 2029 | $11M | $-0.60 | $-1.09–$-0.18 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Ovid Therapeutics Inc. Common Stock
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
www.ovidrx.com- Employees
- 23
- IPO / List date
- May 5, 2017
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds OVID.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,104,300 | $2.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OVID yet.
